表紙
市場調査レポート

高ビリルビン血症:世界の治験レビュー

Hyperbilirubinemia Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 302390
出版日 ページ情報 英文 65 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
高ビリルビン血症:世界の治験レビュー Hyperbilirubinemia Global Clinical Trials Review, H1, 2014
出版日: 2014年05月15日 ページ情報: 英文 65 Pages
概要

当レポートでは、高ビリルビン血症に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤などの情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

  • 高ビリルビン血症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国
    • 欧州の主要5ヶ国
    • 北米の主要国
    • 中東・アフリカの主要国
    • 中南米の主要国

G7諸国での治験件数:代謝性疾患治験全体における高ビリルビン血症の割合

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:代謝性疾患治験全体における高ビリルビン血症の割合

E7諸国での治験件数:フェーズ(相)別

E7諸国での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • 高ビリルビン血症治療薬の治験に参加している上位企業

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概要
    • InfaCare Pharmaceutical Corporation
    • Mednax, Inc.
  • 代表的な研究機関・病院の治験の概要
    • Mashhad University of Medical Sciences
    • University of Rochester
    • Eunice Kennedy Shriver National Institute of Child Health and Human Development
    • Kermanshah University of Medical Sciences
    • University Medical Center Groningen
    • University of California, San Francisco
    • Radboud University
    • Cirujanos la Serena
    • Nanjing Medical University
    • Children's Oncology Group

5つの代表的な治験のプロファイル

付録

図表一覧

目次
Product Code: GDHC2139CTIDB

GlobalData's clinical trial report, "Hyperbilirubinemia Global Clinical Trials Review, H1, 2014" provides data on the Hyperbilirubinemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperbilirubinemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperbilirubinemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Hyperbilirubinemia
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Hyperbilirubinemia to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Hyperbilirubinemia to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Hyperbilirubinemia Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • InfaCare Pharmaceutical Corporation
      • Clinical Trial Overview of InfaCare Pharmaceutical Corporation
      • Mednax, Inc.
      • Clinical Trial Overview of Mednax, Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • Mashhad University of Medical Sciences
      • Clinical Trial Overview of Mashhad University of Medical Sciences
      • University of Rochester
      • Clinical Trial Overview of University of Rochester
      • Eunice Kennedy Shriver National Institute of Child Health and Human Development
      • Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development
      • Kermanshah University of Medical Sciences
      • Clinical Trial Overview of Kermanshah University of Medical Sciences
      • University Medical Center Groningen
      • Clinical Trial Overview of University Medical Center Groningen
      • University of California, San Francisco
      • Clinical Trial Overview of University of California, San Francisco
      • Radboud University
      • Clinical Trial Overview of Radboud University
      • Cirujanos la Serena
      • Clinical Trial Overview of Cirujanos la Serena
      • Nanjing Medical University
      • Clinical Trial Overview of Nanjing Medical University
      • Children's Oncology Group
      • Clinical Trial Overview of Children's Oncology Group
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Hyperbilirubinemia Therapeutics, Global, Clinical Trials by Region, 2014*
  • Hyperbilirubinemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Hyperbilirubinemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Hyperbilirubinemia to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014*
  • Hyperbilirubinemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Hyperbilirubinemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Hyperbilirubinemia to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014*
  • Hyperbilirubinemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Hyperbilirubinemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Hyperbilirubinemia Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Hyperbilirubinemia Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Hyperbilirubinemia Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Hyperbilirubinemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by InfaCare Pharmaceutical Corporation, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Mednax, Inc., 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Mashhad University of Medical Sciences, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Rochester, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Kermanshah University of Medical Sciences, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by University Medical Center Groningen, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Radboud University, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Cirujanos la Serena, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Nanjing Medical University, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014*

List of Figures

  • Hyperbilirubinemia Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Hyperbilirubinemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Hyperbilirubinemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
  • Proportion of Hyperbilirubinemia to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014*
  • Hyperbilirubinemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Hyperbilirubinemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Hyperbilirubinemia to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014*
  • Hyperbilirubinemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Hyperbilirubinemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Hyperbilirubinemia Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Hyperbilirubinemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Hyperbilirubinemia Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Hyperbilirubinemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Hyperbilirubinemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top